Yonsei University College of Medicine, Seoul, Korea.
Department of Internal Medicine, Severance Hospital, Endocrine Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Endocrinol Metab (Seoul). 2020 Dec;35(4):858-872. doi: 10.3803/EnM.2020.683. Epub 2020 Dec 23.
Pheochromocytoma and paragangliomas (PPGL) are hereditary in approximately 30% to 40% cases. With the advancement of genetic analysis techniques, including next-generation sequencing (NGS), there were attempts to classify PPGL into molecular clusters. With NGS being applied to clinical settings recently, we aimed to review the results of genetic analysis, including NGS, and investigate the association with clinical characteristics in Korean PPGL patients.
We reviewed the medical records of PPGL patients who visited Severance hospital from 2006 to 2019. We documented the clinical phenotype of those who underwent targeted NGS or had known germline mutations of related genes.
Among 57 PPGL patients, we found 28 pathogenic germline mutations of susceptibility genes. Before the targeted NGS was implemented, only obvious syndromic feature lead to the Sanger sequencing for the specific genes. Therefore, for the exact prevalence, only patients after the year 2017, when targeted NGS was added, were included (n=43). The positive germline mutations were found in 14 patients; thus, the incidence rate is 32.6%. Patients with germline mutations had a higher likelihood of family history. There were significant differences in the type of PPGLs, percentage of family history, metastasis rate, presence of other tumors, and biochemical profile among three molecular clusters: pseudohypoxic tricarboxylic acid cycle-related, pseudohypoxic von Hippel-Lindau (VHL)/endothelial PAS domain-containing protein 1-related, and kinase-signaling group. Germline mutations were identified in seven PPGL-related genes (SDHB, RET, VHL, NF1, MAX, SDHA, and SDHD).
We report the expected prevalence of germline mutations in Korean PPGL patients. NGS is a useful and accessible tool for genetic analysis in patients with PPGLs, and further research on molecular classification is needed for precise management.
嗜铬细胞瘤和副神经节瘤(PPGL)在大约 30%至 40%的病例中具有遗传性。随着基因分析技术的进步,包括下一代测序(NGS),人们试图将 PPGL 分为分子簇。随着 NGS 最近在临床环境中的应用,我们旨在回顾遗传分析的结果,包括 NGS,并研究其与韩国 PPGL 患者临床特征的关联。
我们回顾了 2006 年至 2019 年期间在 Severance 医院就诊的 PPGL 患者的病历。我们记录了接受靶向 NGS 或具有相关基因种系突变的患者的临床表型。
在 57 名 PPGL 患者中,我们发现了 28 个易感性基因的致病性种系突变。在实施靶向 NGS 之前,只有明显的综合征特征才会导致特定基因的 Sanger 测序。因此,对于确切的患病率,仅包括 2017 年以后(即添加靶向 NGS 时)的患者(n=43)。在 14 名患者中发现了种系突变,因此,发病率为 32.6%。种系突变患者更有可能有家族史。在假缺氧三羧酸循环相关、假缺氧 von Hippel-Lindau(VHL)/内皮 PAS 结构域蛋白 1 相关和激酶信号转导组三个分子簇之间,PPGL 类型、家族史百分比、转移率、其他肿瘤存在和生化特征存在显著差异。在 7 个与 PPGL 相关的基因(SDHB、RET、VHL、NF1、MAX、SDHA 和 SDHD)中发现了种系突变。
我们报告了韩国 PPGL 患者种系突变的预期患病率。NGS 是 PPGL 患者遗传分析的有用且易于获得的工具,需要进一步研究分子分类,以实现精确管理。